SAVA - Cassava Sciences, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.2745
+0.0045 (+0.35%)
As of 11:06AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close1.2700
Open1.2800
Bid1.2800 x 3000
Ask1.3000 x 3000
Day's Range1.2700 - 1.3000
52 Week Range0.2200 - 2.9900
Volume13,853
Avg. Volume334,678
Market Cap21.946M
Beta (3Y Monthly)2.21
PE Ratio (TTM)N/A
EPS (TTM)-0.2740
Earnings DateOct 28, 2019 - Nov 1, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2012-12-13
1y Target Est3.00
Trade prices are not sourced from all markets
  • GlobeNewswire

    Cassava Sciences Initiates Phase 2b Clinical Study in Alzheimer’s Patients

    PTI-125 is a small molecule that targets the massive neuroinflammation and neurodegeneration observed in the Alzheimer’s brain. In conjunction with the initiation of this Phase 2b study, Cassava Sciences also reported dosing of the first two patients for this study, both of which were uneventful.  This Phase 2b study is supported by a research grant award from the National Institutes of Health (NIH).

  • Failure of Alzheimer’s Disease Study Creates a New Penny Stock
    Bloomberg

    Failure of Alzheimer’s Disease Study Creates a New Penny Stock

    (Bloomberg) -- Neurotrope Inc. plunged as much as 82%, falling below a dollar, after a placebo worked better than the company’s experimental treatment for Alzheimer’s disease.Bryostatin-1 showed a 1.3 point improvement on a score judging patients’ mental impairment after three months of treatment while patients getting a placebo treatment had a 2.1 point improvement. The stock fell as low as 81 cents -- a record -- on heavy volume more than 35 times the daily average.“We are disappointed in the topline results from the confirmatory Phase 2 study,” the company’s Chief Executive Officer Charles Ryan said in a statement. “Having just received the data, we are conducting a full review to determine potential next steps.”One of the two analysts tracked by Bloomberg who covers Neurotrope, Maxim’s Jason McCarthy, cut his rating to hold from buy, and removed his $16 price target on the company. He said he was awaiting clarity on if there will be a path forward for bryostatin.Drug developers have been racking up failures in Alzheimer’s as they seek to find a cure for this scourge of aging. Biogen Inc.’s disappointing March results for a drug targeting beta amyloid -- a plaque that builds up in the brain of Alzheimer’s patients -- rocked the market.Drugmakers are persisting nevertheless. Biogen, Eli Lilly & Co., Roche Holding AG as well as small-cap Cassava Sciences Inc. are developing new medicines that target a pathway called tau. Cassava reported its own early results Monday morning, focused on biomarkers of the disease. Cassava’s stock fell 9.3% at 2:25 p.m. The decline could be the result of pressure from Neurotrope’s failure, McCarthy said. Or it could be due to the small size of the study, which included just 13 patients. McCarthy rates Cassava a buy.(Updates to add analyst commentary in fourth and sixth paragraphs)To contact the reporter on this story: Cristin Flanagan in New York at cflanagan1@bloomberg.netTo contact the editors responsible for this story: Catherine Larkin at clarkin4@bloomberg.net, Jim Silver, Divya BaljiFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Benzinga

    A Look At Benzinga Pro's Most-Searched Tickers For September 9, 2019

    This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. ACADIA Pharmaceuticals (NASDAQ: ACAD ) shares ...

  • GlobeNewswire

    Cassava Sciences Reports Positive Phase 2a Clinical Results in Alzheimer’s Patients

    Lead drug candidate, PTI-125, significantly decreased key biomarkers of neuroinflammation and neurodegeneration in all study patients (p

  • How Cassava Sciences, Inc. (NASDAQ:SAVA) Can Impact Your Portfolio Volatility
    Simply Wall St.

    How Cassava Sciences, Inc. (NASDAQ:SAVA) Can Impact Your Portfolio Volatility

    If you're interested in Cassava Sciences, Inc. (NASDAQ:SAVA), then you might want to consider its beta (a measure of...

  • GlobeNewswire

    Cassava Sciences to Present at H.C. Wainwright’s 21st Annual Global Investment Conference

    AUSTIN, Texas, Sept. 03, 2019 -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, announced today that Remi Barbier, President & CEO, will.

  • GlobeNewswire

    Cassava Sciences Announces Second Quarter 2019 Financial Results

    AUSTIN, Texas, Aug. 12, 2019 -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biopharmaceutical company developing PTI-125 for Alzheimer’s disease, today reported.

  • What Kind Of Shareholder Owns Most Cassava Sciences, Inc. (NASDAQ:SAVA) Stock?
    Simply Wall St.

    What Kind Of Shareholder Owns Most Cassava Sciences, Inc. (NASDAQ:SAVA) Stock?

    Every investor in Cassava Sciences, Inc. (NASDAQ:SAVA) should be aware of the most powerful shareholder groups...

  • GlobeNewswire

    Cassava Sciences to Present at Maxim Group’s Conference on Alzheimer’s Disease

    Cassava Sciences, Inc. (SAVA), a clinical-stage biotechnology company, announced today that Remi Barbier, its President and CEO, will present at Maxim Group’s conference on Alzheimer’s disease on Wednesday, June 26th, in New York.  Maxim’s conference for investors, titled “Alzheimer’s Disease – What’s Next? Treating Alzheimer’s in a Post-Amyloid World”, will be held at their corporate offices at 405 Lexington Ave in New York. Cassava Sciences’ presentation for this conference is now available on the Company’s website under https://www.cassavasciences.com/company-presentations.

  • GlobeNewswire

    Cassava Sciences Announces New Website Launch

    Cassava Sciences, Inc. (SAVA), a clinical-stage biotechnology company, announced today the launch of its newly designed website, www.CassavaSciences.com.  Cassava Sciences’ new website has extensive information on Alzheimer’s disease, a key focus of the Company’s research and development. Cassava Sciences expects to announce results of its Phase2a study in the second half of 2019, after patient data are analyzed.

  • GuruFocus.com

    Weekly CFO Buys Highlight

    Insiders invest in Vaalco Energy, Dasan Zhone Solutions and Cassava Sciences

  • Cassava Sciences, Inc. (NASDAQ:SAVA) Insiders Increased Their Holdings
    Simply Wall St.

    Cassava Sciences, Inc. (NASDAQ:SAVA) Insiders Increased Their Holdings

    It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...

  • GlobeNewswire

    Cassava Sciences Reports First Quarter 2019 Financial Results

    AUSTIN, Texas, April 29, 2019 -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biopharmaceutical company, today reported financial results for the first quarter ended March 31,.

  • GlobeNewswire

    Cassava Sciences Completes Patient Enrollment for a Phase 2a Study in Patients with Alzheimer’s Disease

    Cassava Sciences, Inc. (SAVA), a clinical-stage biotechnology company, announced the completion of patient enrollment in a clinical study evaluating the safety of its investigational drug, PTI-125, in patients with Alzheimer’s disease.  Cassava Sciences is conducting this Phase 2a study with scientific and financial support from the National Institutes of Health (NIH).